Estimands in Clinical Trials with Treatment switching

On behalf of the Treatment Switching Subteam of EFSPPI European Special Interest Group and ASA Scientific Working Group “Estimands in Oncology”
Estimands in Clinical Trials with Treatment Switching

Presenter: Natalia Kan-Dobrosky, PPD

EFSPI European Special Interest Group and ASA Scientific Working Group “Estimands in Oncology” Working Group members:

Juliane Manitz (EMD Serono)
Hannes Buchner (Staburo GmbH)
Marie-Laure Casadebaig (Celgene)
Vincent Haddad (AstraZeneca)
Fei Jie (Astellas Pharma Global Development)
Emily Martin (EMD Serono)
Rui Tang (Servier Pharmaceuticals)
Godwin Yung (Takeda Pharmaceuticals)
Jiangxiu Zhou (GSK)
Viktoriya Stalbovskaya (Merus)
Yue Shentu (Merck Sharp & Dohme)
Mindy Mo (Amgen)
Jyotirmoy Dey (AbbVie)
Natalia Kan-Dobrosky (PPD)
Introduction

- The need for the Addendum on Estimands and Sensitivity Analysis in Clinical Trials E9 (R1) was identified due to recurrent issues with a lack of clarity in trial objectives and related treatment effect of interest.

- In November 2019, the International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use released an Addendum to E9 guideline on Statistical Principles for Clinical Trials that:
  - Introduced structured framework for clinical trial design
  - Defined intercurrent events, which occur after treatment initiation and affect either the existence or interpretation of the measurement
  - Highlighted the difficulty of assessing treatment effect in the presence of intercurrent events.
Potential Journeys of Cancer Patients in Clinical Trials

Investigational drug

Patient 1
- Discontinued due to PD
- Started new therapy
- Alive

Patient 2
- Discontinued due to AE
- Started new therapy
- Died

Control

Patient 3
- Died on treatment
- Died

Patient 4
- Discontinued due to PD
- Died

Patient 5
- Discontinued due to AE
- Started new therapy
- Died
Potential Journeys of Cancer Patients in Clinical Trials

- Can the prolonged survival be attributed to the investigational drug? 
  or
- Is it the effect of subsequent therapy? 
  or
- What would have been the survival of patients one and two had they not received the new therapies?

- What is the key question of interest? 
  - Survival regardless of whether a patient received another therapy? 
  or
  - Survival had patients not received new therapies?
### Treatment Switching

- Per E9(R1), subsequent therapy is an intercurrent event
- In oncology, the start of new therapy after study treatment discontinuation or treatment switching is a **key intercurrent event**

#### Types of Treatment Switching

<table>
<thead>
<tr>
<th>Description of Treatment Switching</th>
<th>Type of Treatment Switching</th>
</tr>
</thead>
<tbody>
<tr>
<td>From control arm to investigational arm</td>
<td>Crossover*</td>
</tr>
<tr>
<td>From control arm to same drug class as investigational arm</td>
<td>Treatment switching</td>
</tr>
<tr>
<td>From control or investigational arm to a drug (class) of interest</td>
<td>Treatment switching</td>
</tr>
</tbody>
</table>

* In the time-to-event analysis when crossover occurs in an oncology trial. For example, control patients cross over to the experimental treatment when progression is observed, and the interest is in estimating the hypothetical effect on overall survival (OS) when none of the control patients would have crossed over [EMA/845963/2018].
Strategies to Handle Start of New Therapy

- **Treatment policy strategy**
  - Subsequent therapies reflect clinical practice

- **Hypothetical strategy**
  - Subsequent therapies are not clinical practice or were not received

- **Composite strategy**
  - Subsequent therapy is a part of composite endpoint for the OS (not applicable)

- **Principal stratum strategy**
  - Prospectively identifying patients who will take subsequent therapy (difficult to predict/not applicable)

- **While on treatment strategy**
  - Considering survival only prior to the subsequent therapy (not applicable)
Strategies to Handle Start of New Therapy

- **Treatment policy strategy question of interest:** Survival benefit of investigational drug regardless of what happens after treatment discontinuation
  - It is assumed that subsequent therapies given after treatment discontinuation reflect clinical practice
  - This strategy corresponds to the ITT approach
  - Might be not a meaningful strategy

- **Hypothetical strategy question of interest:** Survival benefit of investigational drug in the hypothetical scenario in which patients do not receive subsequent therapies, i.e., adjusted for the effect of subsequent therapies
  - Often used as supportive post-hoc analysis in oncology trials after observing treatment policy may not be addressing the clinical question of interest
Current Routine Practice and Motivation

- Traditional analysis of OS in the confirmatory study is performed ignoring treatment switching (treatment policy)

- Survival benefit of investigational treatment is likely to be underestimated when control group patients switch more frequently to treatment prolonging OS

- Treatment landscape in oncology is rapidly changing and is also different from country to country
Treatment Switching Scenario One

- Investigational drug vs. control; both arms can receive subsequent therapies reflecting clinical practice

**Clinical question of interest:**
What is the OS benefit of the investigational drug vs. standard of care (SOC) regardless of subsequent therapies? => Treatment policy strategy
The comparison is between the sequence of investigational drug and other therapies and the sequence of control treatment and other therapies
Treatment Switching Scenario Two

- Investigational drug vs. control; investigational drug is approved as next-line therapy after SOC

Clinical question of interest One:
What is the OS benefit of the investigational drug vs. SOC regardless of subsequent therapies? => Treatment policy strategy, SOC represents sequence of control treatment and investigational drug

Clinical question of interest Two:
What is the OS benefit of the investigational drug vs. SOC had patients not switched to other therapies? => Hypothetical strategy, comparison between investigational drug and SOC
Treatment Switching Scenario Three

- Investigational drug vs. control with crossover to not yet approved investigational drug

Clinical question of interest:
What is the OS benefit of the investigational drug vs. SOC if crossover opportunity does not exist? => Hypothetical strategy could be more informative for clinicians and patients
Challenges to Select Most Meaningful Strategy

- Scenarios demonstrate the importance of multidisciplinary discussions at study design stage.

- Knowledge of competitive landscape is critical to ensure the main research question with regard to OS is identified. SOCs are likely to be different between countries.

- Scenarios are theoretical examples. However, multinational trials can be much more complex. Most trials in oncology will be a mixture of the scenarios.

- Different stakeholders (patients, clinicians, payers, etc.) might define different SOCs for different patient populations within the same trial (e.g., Ibrutinib trial was split into three populations by German GB-A [federal joint committee], according to their definition of appropriate comparator therapies)
Estimand Regardless of Treatment Switching (Treatment Policy)

- Objective is to evaluate OS benefit assuming that switching is not associated with survival/covariates.
- The treatment policy estimand is defined as time from randomization to death regardless of treatment changes.
- Analysis method is standard proportional hazards Cox model and is guided by treatment policy strategy to handle treatment switching.
- This estimand may not be clinically relevant due to systematic treatment switching. If switching is associated with survival, then the treatment effect may be underestimated.
- Following Fleming et al. (2009) it is recommended to present treatment policy estimand along with other more meaningful estimands.
Estimand for Treatment Switching (Hypothetical Strategy with IPCW)

- Estimand that evaluates the OS benefit adjusted for treatment switching is defined as the time from randomization to death while the start of any subsequent therapy before death, is handled by hypothetical strategy.

- Analysis method is Cox model with inverse probability censoring weighting (IPCW) (Robins JM et al., 2000).

- IPCW assumes that “patients who do not switch serve as proxies for those who do.” Informative censoring introduced by censoring at treatment switching is adjusted by weighting remaining observations using baseline and time-dependent covariates.

- Key assumption: no unmeasured confounders.
Estimands for Crossover (Hypothetical Strategy with RPSFT)

- Estimand that evaluates OS benefit adjusted for treatment crossover is defined as the time from randomization to death and the intercurrent event of crossover is handled by hypothetical strategy.

- Analysis method is Cox model with counterfactual survival times for crossover patients from rank preserving structural failure time (RPSFT) approach (Robins JM et al., 1991; Branson M et al., 2002).

- RPSFT refers to a model-based approach that adjusts the survival time of patients, who switch from the control arm to the investigational arm.
Estimands for Crossover at Progression (Hypothetical Strategy with Two-Stage Method)

- Estimand that evaluates OS benefit adjusted for treatment crossover at a specific disease-related time point, typically progression, and the survival time after progression is adjusted using hypothetical strategy.

- Analysis method is based on reconstructed survival times obtained by the two-stage approach (Latimer NR et al. 2014).

- The two-stage approach defines a secondary baseline by a specific disease-related time-point, e.g., progression, at which crossover is possible.

- Secondary baseline requires complete data collection of the disease-related time point. It also assumes that switching occurs soon after that time. Another assumption is about no unobserved confounders at the secondary baseline.
Summary

- Standard practice should be to account for treatment switching in the analysis during the planning stage of the trial to incorporate that into design and data collection strategies.

- Estimand where treatment switching is handled with treatment policy is meaningful in most situations and is appropriate if subsequent therapies reflect clinical practice.

- In situations when subsequent therapies are not clinical practice other estimands handling treatment switching with hypothetical strategy are more versatile.

- Other than hypothetical strategies, principal stratum or composite strategies could be considered to handle intercurrent event of treatment switching.
References


- EMA/845963/2018, Human Medicines Research and Development Support Division Question and answer on adjustment for cross-over in estimating effects in oncology trials.
Copyright ©2021 PPD, Inc. All rights reserved. This presentation, including the information contained herein and commentary associated herewith ("materials"), is provided as a service of PPD. These materials, based on publicly available information as well as the knowledge and experience of PPD’s employees, have been prepared solely for informational and educational purposes and should not be relied upon for professional advice. Any further use of these materials requires the express written consent of PPD.